Looz Enema

Quick links to important sections

Looz Enema

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Looz Enema

Quick Facts

Property Description
Active ingredient Lactulose
Form Solution for enema
Pharmacological class Osmotic Laxative and Ammonium Detoxicant
General purpose Relieves constipation and reduces ammonia levels
Origin Synthetic disaccharide

What Type of Medicine is Looz Enema?

Looz Enema is a specialized pharmaceutical preparation defined by the active substance, Lactulose. It carries a dual therapeutic classification: it is categorized primarily as an osmotic laxative and secondarily as an ammonium detoxicant, or colonic acidifier. The preparation functions as a hyperosmotic agent, a role associated with the management of chronic constipation. This dual function is significant, as Looz Enema is utilized both for constipation relief and in clinical contexts to help manage excess ammonia levels in the systemic circulation.

Lactulose Composition, Origin, and Rectal Form

The core of Looz Enema is Lactulose, a synthetic disaccharide compound derived from the milk sugar lactose through chemical isomerization. Structurally, the compound consists of one molecule of galactose and one molecule of fructose. Lactulose is poorly absorbed by the human small intestine, with only a very small percentage reaching the bloodstream, which allows it to remain localized in the bowel.

Manufactured as a solution for enema, this liquid preparation is intended specifically for rectal administration. This rectal form serves as a distinctive application compared to oral solutions when localized action in the colon is required. The composition consists of the active Lactulose dissolved in an aqueous solution, which may contain small, measurable quantities of residual sugars, such as galactose and lactose, from the manufacturing process.

Regulatory References

  1. NIH: Lactulose - StatPearls

What side effects are possible with Looz Enema?

Possible Side Effects and Safety Information

The official safety profile for Lactulose, the active ingredient in Looz Enema, is structured around the product’s expected osmotic effects and documented risks. Adverse reactions are formally classified by frequency, with the majority of effects concerning the gastrointestinal system.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped by the physiological system affected, following regulatory standards. The frequency classifications may include:

Classification System-Organ Class Affected Examples of Documented Effects
Very Common Gastrointestinal disorders Diarrhea
Common Gastrointestinal disorders Flatulence, Abdominal pain, Nausea, Vomiting
Not Known Immune system disorders Hypersensitivity reactions, rash, pruritus

Safety Considerations and Restrictions

Serious consequences documented in official labeling primarily relate to systemic disturbance following excessive use. Electrolyte imbalance and dehydration are noted as potential risks associated with chronic use of unadjusted high doses or misuse, due to prolonged diarrhea. For certain patients in poor general condition or older adults, periodic electrolyte monitoring may be indicated with use lasting longer than six months.

Specific safety restrictions prohibit the use of this medicine in individuals with Galactosaemia or those with gastrointestinal obstruction, including suspected perforation. The presence of residual sugars also warrants caution when the product is administered in high doses to diabetic patients, as defined in official regulatory documents.

Overdose and Emergency Response

The official regulatory descriptions state that an overdose of Lactulose, the active ingredient in Looz Enema, is characterized by the exaggeration of its osmotic effect in the bowel. The documented clinical manifestations are severe gastrointestinal signs, specifically diarrhoea and significant abdominal pain or cramps.

The severe consequence of overdosage is the critical risk of extensive fluid loss and the resulting electrolyte imbalance. The official prescribing information lists the potential for serious outcomes, including specific disturbances like hypokalemia (low potassium) and hypernatremia (high sodium), which stem from the physiological stress of the fluid deficit.

When immediate medical help must be sought: Urgent medical care is required when the severe manifestations of overdosage occur, particularly when there are clinical signs of significant fluid loss or electrolyte disturbance. Official regulatory guidance mandates that if extensive fluid loss is present, the immediate correction of electrolyte disturbances is a necessary medical action.

Official Management Procedures: The regulatory context confirms that no specific antidote is known for Lactulose overdose. Therefore, management is confined to supportive care, beginning with the cessation of treatment or dose reduction. The subsequent focus of medical management is providing symptomatic treatment to manage the gastrointestinal distress and correct the documented fluid and electrolyte deficits.

Therapeutic Uses of Looz Enema

What Looz Enema Treats: Main Uses and Benefits

This medication is commonly used across therapeutic domains involving both gastrointestinal function and symptoms related to systemic imbalance. It helps address symptom clusters that may become intense and disruptive in two main areas, providing supportive management for severe constipation, fecal impaction, and symptoms of hepatic encephalopathy.


Relief for Severe Constipation and Fecal Impaction

This medicine is relevant for easing symptoms related to physical discomfort and functional strain associated with difficult bowel evacuation. It is used for managing the intense straining, infrequent movements, and discomfort of hard or impacted stool, particularly in conditions presenting with systemic or localized discomfort. Its primary benefit contributes to improved comfort and supports a regular, manageable bowel rhythm by assisting with the symptoms associated with severe, difficult-to-manage constipation.


Symptomatic Management and Supportive Contexts

Looz Enema is applied in clinical settings that involve acute or unstable symptom patterns, such as conditions marked by increased physiological stress from liver disease. This application is used for managing symptoms of increased neurological activity like mental confusion and disorientation, which are linked to systemic imbalance. The resulting symptomatic relief contributes to easing the overall symptom burden, particularly the manifestations of neurological discomfort. This use is also relevant when supportive symptom management is appropriate, often during phases when symptoms become more noticeable following procedures, where it may assist with supporting overall functional stability by supporting the passage of soft stool and assisting with minimizing effort during evacuation.


Quick Fact Relief for
Primary Domain Symptoms of severe constipation and fecal impaction
Secondary Domain Neurocognitive symptoms linked to systemic ammonia imbalance

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for Looz Enema: Official Regulatory Summary

Official regulatory documents strictly define the population groups permitted or prohibited from using Looz Enema (Lactulose).


Contraindications (Must Not Use)

Use is absolutely prohibited in patients diagnosed with galactosaemia or those who require a low galactose diet due to the drug's residual sugar content. The medicine is also contraindicated in cases of known or suspected gastrointestinal obstruction, digestive perforation, or severe conditions such as acute inflammatory bowel disease.

Conditional and Restricted Use

  • Pediatric Population: Safety and effectiveness are not established in children, and use must be under medical supervision.
  • Diabetic Patients: Use requires caution due to the presence of unabsorbed sugars (galactose and lactose).
  • Pregnancy/Lactation: Use during pregnancy is permitted only if clearly needed (Category B). Caution is exercised in nursing mothers as excretion into human milk is unknown.
  • Older Adults: While generally permitted, long-term use (over six months) requires periodic control of serum electrolytes, as stipulated by regulatory labels.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific drug and product constraints that may alter the intended effect of lactulose or create a safety concern under certain conditions.

Interaction Type Interacting Product(s) Official Constraint / Requirement
Effect Inhibition (pH-related) Nonabsorbable Antacids Co-administration may inhibit the required decrease in colonic pH induced by lactulose, potentially leading to a lack of desired therapeutic effect.
Effect Inhibition (Microbial) Oral Anti-infective Agents (e.g., Neomycin) May interfere with the bacterial degradation of lactulose required for its activity, necessitating caution and monitoring of the clinical response.
Interference with Assessment Other Laxatives Generally not recommended, especially during the initial phase of therapy for portal-systemic encephalopathy, as loose stools may falsely suggest that an adequate lactulose dose has been achieved.
Reduced Efficacy pH-Sensitive Medicines (e.g., Mesalazine, Corticosteroid Enemas) The acidification of colonic contents by lactulose may theoretically reduce the efficacy of certain medicines whose release or function is pH-dependent.

Procedural Safety Constraint

A theoretical hazard exists for patients undergoing electrocautery procedures (e.g., proctoscopy, colonoscopy) while on lactulose therapy. Due to the accumulation of H2 gas, a thorough bowel cleansing with a non-fermentable solution is required prior to the procedure to mitigate the risk of an explosive reaction.

Mechanism of Action

How Looz Enema Works

The mechanism of Looz Enema relies on the localized action of unabsorbed Lactulose within the colon, engaging in two distinct but complementary physiological processes that govern its effect profile.

Osmotic Fluid Modulation and Peristalsis Stimulation

The drug remains poorly absorbed until it reaches the large intestine, where its high concentration creates a hyperosmotic gradient. This gradient initiates net fluid secretion, drawing a large volume of water from the body’s circulation into the gut lumen. This osmotic influx, combined with the chemical irritation from microbially generated short-chain fatty acids (SCFAs), directly stimulates the smooth muscle cells of the colon wall. This physiological response increases the frequency and force of peristaltic contractions, moving the softened, bulkier contents toward the rectum.

pH-Dependent Ion Trapping for Nitrogenous Waste Equilibrium

The secondary action is a chemical-biological cascade dependent on the colonic microflora, which metabolizes the disaccharide via enzymatic action into SCFAs. The accumulation of these organic acids significantly lowers the pH of the large bowel contents. This acidification drives the chemical conversion of highly diffusible, readily absorbed ammonia ( NH3) into the charged, non-diffusible ammonium ion ( NH4^+). Since charged ions cannot readily cross the intestinal membrane, this process prevents the re-entry of nitrogenous waste into the portal circulation, binding the compound until it is physically carried from the body.

Dosage and Administration Information

Administration Route and Context

The administration of this medicine is restricted to the rectal route, delivered as a specialized retention enema. This method is typically reserved for acute clinical settings, such as managing stages of portal-systemic encephalopathy, particularly when the patient is unable to receive the standard Lactulose regimen orally. The use of this preparation is meant to be a temporary intervention.

Official Dosing and Preparation Standards

Official instructions mandate the precise preparation of the solution prior to administration. A single dose consists of a total prepared volume of 1,000 mL (1 Liter). This volume is created by combining 300 mL of the Lactulose solution with 700 mL of a suitable diluent, which can be either water or physiological saline. This standard preparation delivers approximately 200 grams of Lactulose.


Frequency and Procedural Instructions

Usage Instruction Standard Requirement
Retention Time The prepared solution must be retained for 30 to 60 minutes to achieve the necessary therapeutic effect.
Repetition Interval Dosing may be repeated every 4 to 6 hours as required for acute management.
Immediate Re-dosing If the solution is inadvertently evacuated too soon, the dose may be administered again immediately.
Transition Pattern Oral Lactulose therapy must be initiated before the rectal administration is completely discontinued.
Exclusionary Rule Cleansing enemas containing alkaline agents or soap suds must not be used concurrently.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Looz Enema

Evidence for use in Overt Hepatic Encephalopathy

Research explored the use of Looz Enema in managing neurocognitive symptoms of Overt Hepatic Encephalopathy (HE). Studies included short-term Randomized Controlled Trials (RCTs) focused on adult patients with deep-grade HE. Researchers monitored outcomes related to systemic imbalance, such as shifts in blood ammonia concentration, and changes in neurological status. Studies examined how the time to change in encephalopathy grade compared between rectal lactulose and control treatments. Long-term effects are not fully established, and ethical constraints limit the availability of new, large-scale RCTs for severe HE.

Evidence for use in Severe Constipation and Fecal Impaction

The drug was evaluated in contexts where rapid, localized action is sought, such as managing severe constipation or fecal impaction. Research primarily monitored outcomes related to physical discomfort and functional imbalance, including Bowel Movement Frequency (BMF) and stool consistency. Most randomized evidence exploring these outcomes was observed in trials using the oral form of lactulose for chronic use, rather than the rectal solution for acute episodes. Consequently, direct research data specific to the enema formulation for routine relief is limited.

Study Limitations and Evidence Gaps

The research base includes limitations such as modest sample sizes in some focused enema-specific trials. Comparative evidence is lacking regarding rectal lactulose versus other rectal interventions for acute impaction. For all uses, limited information is available for long-term outcomes or maintenance of effects. Research has been observed in geriatric patients and critically ill adults, but data for certain groups remain insufficient to fully characterize the research base.

Key Studies & References Rectal Lactulose Induces Hypernatremia and Increases Mortality in Patients with Cirrhosis and Hepatic Encephalopathy

Frequently Asked Questions (FAQ)

Common questions about Looz Enema (FAQ)

Q: How quickly does Looz Enema usually start to work?

Official product information indicates that for the management of portal-systemic encephalopathy (PSE), the time to clinical improvement can vary. While some patients may show improvement within 24 hours, the expected onset of significant change may not be observed until 48 hours or longer.


Q: Do regulatory agencies classify Looz Enema as an over-the-counter or prescription-only product?

Regulatory documents classify the Lactulose solution for rectal administration, such as Looz Enema, as a prescription-only (Rx) medication. This means it is administered only under the direction and supervision of a licensed healthcare provider.


Q: Does Looz Enema carry a Black Box Warning, according to the FDA?

According to the FDA and other official regulatory sources, the drug’s labeling does not include a Black Box Warning. This type of warning is typically reserved for drugs with the most serious safety concerns.


Q: What types of foods or drinks should be noted when using Looz Enema?

Official guidance specifies that patients requiring a low-galactose diet should note the residual sugars, such as galactose and lactose, present in the solution. Due to the presence of these sugars from the manufacturing process, the medicine is contraindicated in patients with galactosaemia.


Q: Is Looz Enema known to cause changes in urine output?

While official safety data does not list common changes to urine output, decreased urination has been noted as a potential side effect in some cases. This is typically observed in situations of excessive use or misuse that leads to severe diarrhea, which can result in dehydration and electrolyte imbalance.


Q: Are there any known interactions between Looz Enema and herbal supplements?

Official regulatory documents emphasize the importance of disclosing all products being used, including herbal supplements, to a healthcare professional. Specific known interactions between Looz Enema and most herbal supplements are not generally listed in the regulatory documents.


Q: Is Looz Enema available under different brand names in other countries?

The active ingredient in Looz Enema, lactulose, is available under various brand names in different global regions. Examples of these alternative names include Duphalac, Constulose, and Enulose.


Q: Are headaches a noted potential side effect of Looz Enema?

Headaches are not classified among the common side effects of the medication. However, a severe headache is noted in the literature as one of the serious neurological symptoms that may be experienced in the management of portal-systemic encephalopathy, and may indicate the need for prompt evaluation by a healthcare professional.


Q: Why is Looz Enema sometimes used before a medical procedure?

Official warnings highlight a procedural safety constraint for patients undergoing electrocautery procedures, such as a colonoscopy. Since the drug’s action can lead to the accumulation of hydrogen gas, regulatory guidelines specify that thorough bowel cleansing with a non-fermentable solution is necessary before the procedure to mitigate the risk of an explosive reaction.


Q: What are the recognized signs of an allergic reaction to Looz Enema?

Signs of a severe allergic reaction, or hypersensitivity, are noted in regulatory information. These signs can include rash, hives, and itching, as well as more serious symptoms such as wheezing, tightness in the chest or throat, and swelling of the mouth, face, lips, tongue, or throat.


Q: What is the primary route of excretion for the active component of Looz Enema?

Official pharmacological data indicates that lactulose is very poorly absorbed by the body, with 3% or less reaching the bloodstream to be excreted by the kidneys. The vast majority of the dose remains localized in the colon, where it is broken down by colonic bacteria and ultimately expelled from the body through the stool via the medicine's laxative effect.


Q: What are the common misunderstandings about how Looz Enema should be used?

Official guidance defines several strict rules for administration that are intended to prevent user error. These rules state that, according to the label, the enema is meant to be retained for 30 to 60 minutes for the proper effect, and that a transition to oral lactulose therapy is typically initiated before rectal use is discontinued. Importantly, the solution is prohibited from concurrent use with alkaline cleansing enemas or soap suds.


Q: What is the general level of effectiveness described in regulatory summaries for Looz Enema?

Studies summarized in regulatory documents indicate a clinical response rate of approximately 75% in patients being treated for high blood ammonia levels. The effectiveness is described as being at least as satisfactory as that resulting from neomycin therapy, according to clinical data.


Q: Is Looz Enema considered a first-line treatment for its primary indication?

The rectal solution is not described as a first-line or routine treatment. Instead, official documents indicate that its use is generally reserved for acute clinical settings, specifically when a patient is unable to receive the standard oral lactulose regimen.


Q: Does Looz Enema contain any preservatives or inactive ingredients of note?

The solution contains the active ingredient lactulose and is diluted with water or saline for administration. A notable component is the presence of residual sugars, specifically galactose and lactose, which are remnants of the manufacturing process.


Q: Are there documented cases of overdose with Looz Enema, and what are the expected effects?

Overuse or accidental overdose may cause symptoms such as nausea, vomiting, and stomach cramps. A more serious concern is the potential for severe electrolyte imbalance, which can lead to symptoms like confusion, weakness, and an irregular heartbeat. Severe diarrhea is an official sign that the dose may be too high.


Q: What is the relationship between Looz Enema and the production of lactic acid?

The medicine’s function relies on its metabolism by colonic bacteria, which break the lactulose down into organic acids. This process primarily produces lactic acid, along with small amounts of formic and acetic acids. The accumulation of these acids lowers the pH in the large bowel, which is essential for the drug’s intended effect.

How should Looz Enema be stored and disposed of?

How to Store and Dispose of Lactulose Solution

Storage and disposal requirements for Lactulose solution (Looz Enema) are defined by regulatory documents to maintain product integrity and safety.

Storage Conditions

The solution must be stored at Controlled Room Temperature, which is defined as a temperature range between 15 C and 30 C (59 F to 86 F). The product must be stored Keep out of reach of children.

Storage Rule Requirement
Temperature 15 C to 30 C
Freezing/Cold May cause slight darkening, but potency is unaffected.

Disposal Instructions

Unused or expired Lactulose solution should not be disposed of in household trash or wastewater unless specifically instructed. Instead, the official guidance requires that the product be disposed of according to local regulations, often utilizing authorized drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Looz Enema found in:

A-Z Index: